A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011302/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared to adults 65 years and above.
提供机构：
Vivli
创建时间：
2025-04-15
